The experimental study of anti-inflammatory properties of the drug “Diclocor”

O. S. Popov, S. Shebeko, O. Shevchenko, A. Shalamay
{"title":"The experimental study of anti-inflammatory properties of the drug “Diclocor”","authors":"O. S. Popov, S. Shebeko, O. Shevchenko, A. Shalamay","doi":"10.24959/cphj.15.1363","DOIUrl":null,"url":null,"abstract":"Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used groups of medicines. Despite the undeniable clinical effectiveness, their use is associated with the risk of side effects. This fact directs scientific research to searching combinations of NSAIDs with other substances in order to identify compositions which will allow reducing the dose of the NSAID without losing its anti-inflammatory effectiveness. In view of all this, a new combined drug “Diclocor” developed by “Borshchahivskiy CPP” (Ukraine) is of interest. The article presents the results of the experimental study of the anti-inflammatory effect of the combined drug “Diclocor” in comparison with its active monocomponents – diclofenac sodium and quercetin. The alterative stage of inflammation was studied on the model of scarified wounds, the exudative stage – on the model of carrageenin edema, and the proliferative stage – on the model of cotton pellet-induced granuloma. All studies were conducted in rats. The experimental results have shown the superiority of Diclocor in influencing on all three stages of inflammation compared to the reference drugs in the appropriate doses. Diclocor has exhibited the most pronounced effect on the stages of alteration and exudation, and can be described as a promising drug for the treatment of proliferative and destructive inflammatory diseases.","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"30 1","pages":"35-39"},"PeriodicalIF":0.0000,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24959/cphj.15.1363","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used groups of medicines. Despite the undeniable clinical effectiveness, their use is associated with the risk of side effects. This fact directs scientific research to searching combinations of NSAIDs with other substances in order to identify compositions which will allow reducing the dose of the NSAID without losing its anti-inflammatory effectiveness. In view of all this, a new combined drug “Diclocor” developed by “Borshchahivskiy CPP” (Ukraine) is of interest. The article presents the results of the experimental study of the anti-inflammatory effect of the combined drug “Diclocor” in comparison with its active monocomponents – diclofenac sodium and quercetin. The alterative stage of inflammation was studied on the model of scarified wounds, the exudative stage – on the model of carrageenin edema, and the proliferative stage – on the model of cotton pellet-induced granuloma. All studies were conducted in rats. The experimental results have shown the superiority of Diclocor in influencing on all three stages of inflammation compared to the reference drugs in the appropriate doses. Diclocor has exhibited the most pronounced effect on the stages of alteration and exudation, and can be described as a promising drug for the treatment of proliferative and destructive inflammatory diseases.
“双氯乐”抗炎作用的实验研究
非甾体抗炎药(NSAIDs)是使用最广泛的药物之一。尽管无可否认的临床效果,它们的使用与副作用的风险有关。这一事实指导科学研究寻找非甾体抗炎药与其他物质的组合,以确定既可以减少非甾体抗炎药的剂量又不会失去其抗炎效果的成分。鉴于这一切,“Borshchahivskiy CPP”(乌克兰)开发的一种新的联合药物“Diclocor”引起了人们的兴趣。本文介绍了联合用药双氯芬酸钠和槲皮素与其有效单成分双氯芬酸钠抗炎作用的实验研究结果。以结疤创面为模型,观察炎症的交替期,以卡拉胶性水肿为模型,观察炎症的渗出期,以棉粒性肉芽肿为模型,观察炎症的增殖期。所有的研究都在大鼠身上进行。实验结果表明,在适当的剂量下,与对照药物相比,双氯胺酮对所有三个阶段炎症的影响都具有优势。Diclocor对改变和渗出的阶段表现出最显著的影响,可以被描述为治疗增殖性和破坏性炎症性疾病的有希望的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信